

Congress of the United States
House of Representatives

COMMITTEE ON OVERSIGHT AND REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5051

MINORITY (202) 225-5074

<http://oversight.house.gov>

September 27, 2019

Mr. Richard A. Gonzalez
Chairman and Chief Executive Officer
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064

Dear Mr. Gonzalez:

On January 14, 2019, the Committee sent a letter to AbbVie requesting documents and information regarding your company's pricing practices for two drugs, Humira and Imbruvica. On June 21, 2019, the Committee sent a follow-up letter requesting your full compliance by July 18, 2019.

These requests are part of the Committee's broad investigation into drug pricing practices by 12 major pharmaceutical companies. The Committee's investigation seeks to determine the reasons AbbVie increased the prices of Humira and Imbruvica, how AbbVie is using the revenues from sales of these drugs, and what Congress can do to alleviate the pressure placed on our healthcare system as a result of these price increases.

To date, AbbVie's responses have been woefully inadequate. AbbVie has sent multiple letters with responses to some of the Committee's requests, but your company has failed to provide key materials, including board materials and communications relating to pricing strategies and lifecycle management regarding Humira and Imbruvica. AbbVie has also failed to produce communications regarding its acquisition of Pharmacyclics and regarding executive compensation.

Following the Committee's June 21 letter, counsel for AbbVie informed Committee staff that the company was reviewing the requested communications and would provide a significant production of responsive documents by July 18, 2019, with further productions to follow. On July 18 and August 8, 2019, your counsel reiterated these commitments and provided documents that were asserted to be responsive. However, the documents provided were grossly inadequate and incomplete.

For example, the documents regarding Humira provided in response to the Committee's request for communications regarding pricing strategies or lifecycle management did not contain the types of decision-making communications sought through this request. Instead, the company produced primarily external newsletters with publicly-available information and widely-


Mr. Richard A. Gonzalez
Page 2

distributed emails notifying AbbVie's sales force about changes to Humira's formulary position. While the company provided some relevant documents relating to Imbruvica, the response appears to be missing a significant number of documents and communications.

The Committee insists that AbbVie produce, by October 18, 2019, a complete set of documents and communications responsive to the January 14, 2019 requests, including specifically Requests 4(d), 7(a), 9, and 10(a)-(d). If AbbVie fails to provide a complete response by this date, the Committee will consider issuing a subpoena.

Please contact Committee staff at (202) 225-5051 if you have any questions.

Sincerely,


Elijah E. Cummings
Chairman

cc: The Honorable Jim Jordan, Ranking Member